Clinical Research Wenyangkaiqiaofang Of Deficiency Type Of Vascular Dementia

Objective:Watch Wenyangkaiqiaofang in the treatment of kidney yang mild to moderate vascular dementia safety and clinical efficacy to Western control group Piracetam tablets compare to discuss Wenyangkaiqiaofang treat kidney theoretical basis for the virtual type of vascular dementia.Methods:The topic will meet inclusion criteria deficiency type light from the First Affiliated Hospital of Henan Medical College hospital inpatient encephalopathy60cases, moderate vascular dementia, according to a randomized, single-blind, parallel comparison of the average ratio of1:1Western medicine and Chinese medicine into the control group30patients in each treatment group. Western drugs of choice in the control group was Piracetam tablets, oral,3/time,3times/day for a course of treatment for12weeks, once a month telephone follow-up. Chinese medicine treatment group drugs of choice are Wenyangkaiqiaofang granules, water, about200ml/times,2times/day for a course of treatment for12weeks, once a month telephone follow-up. Differences between the two groups were observed before and after treatment in the laboratory related observations (lipids, homocysteine, etc.), the cognitive function (MMSE score), the daily capacity (ADL points), the TCM symptom scores before and after the terms of regularly fill clinical observation scale, and the safety and clinical drug markedly effective rate, the total efficiency of analysis and evaluation.Results:The two groups were tested during the treatment group lost one case, the control group lost one case, after the case was found in the control group included one patient clinical information and data collection is not complete, so the final number of cases was completed effective treatment group of29patients, control group of28cases.The two groups after treatment the following results:(1) Total Clinical efficacy:treatment group of29patients,1patient, effective in12cases, effective in13cases,3cases of clinical control, markedly effective rate of55.2%, the total efficiency of96.6%; control group of28cases,3cases, effective in14cases,9cases clinical control of two cases, markedly effective rate of39.3%, the total efficiency of89.3%. The statistical analysis chi-square test, the treatment group and the control group markedly effective rate, the total efficiency has a significant difference (P<0.05), that Wenyangkaiqiaofang significantly better than Piracetam tablets.(2) Laboratory observations:after treatment, patients treated with lipids, homocysteine levels have decreased in varying degrees, by t test, P<0.05, there are great changes in the treatment group; control group Statistically, there was no significant differences. between treatment groups was significantly different (P<0.05), that Wenyangkaiqiaofang in lipids, homocysteine and other laboratory-related factors than the Piracetam tablets improved significantly.(3) The efficacy of integration:the treatment group and control group, respectively, before and after treatment MMSE points (cognitive function) and ADL points (activities of daily living) were compared by statistical analysis, P values<0.05, which means that two groups of drug therapy for patients with cognitive functions there are different degrees of improvement.After treatment groups MMSE score and ADL integral comparison, P values>0.05, indicating that Wenyangkaiqiaofang in terms of cognitive function and activities of daily living with mild to moderate deficiency in patients with vascular dementia and Piracetam tablets the improvement is substantially the same.(4) TCM syndrome:the treatment group than the control group (P<0.05), that Wenyangkaiqiaofang to improve the situation in terms of symptom score in patients with mild to moderate vascular dementia type of deficiency much better than Piracetam tablets.(5) Safety Evaluation:After treatment, blood routine, urine routine, stool routine, electrocardiogram and liver and kidney function were no obvious changes in the course of medication were not found in patients with allergies and other adverse reactions. Two groups of patients were compared after treatment from liver and kidney function were related indicators, the statistical analysis, P values>0.05, indicating Wenyangkaiqiaofang and Piracetam tablets toxic side effects, safe and reliable.Conclusion:By observing this clinical efficacy, Wenyangkaiqiaofang type of deficiency with mild to moderate vascular dementia syndromes points, markedly effective rate, the total efficiency of the clinical observations and laboratory-related indicators (lipids, homocysteine, etc.) aspects more Piracetam tablets significant improvement in cognitive function (MMSE points), activities of daily living (ADL points) and related indicators of liver and kidney function, Wenyangkaiqiaofang and Piracetam tablets substantially the same effect. Description reliable clinical efficacy efficacy Wenyangkaiqiaofang, non-toxic side effects, for the treatment of vascular dementia provides new ideas and methods.